EasyJet needs investors on board as next takeover bid may be serious | Nils Pratley

Wizz Air’s offer was rejected, of course, but £1.2bn rights issue hardly put fizz back into shares

The pandemic has transformed the airline industry in unexpected ways: Wizz Air, whose shares have recovered all the altitude lost in the early months of lockdown, is now bigger in stock market terms than easyJet. The latter’s shares are stuck at half their old level and £3.25bn valuation now compares with £5bn for Wizz.

The position is quite a comedown for easyJet, and Wizz’s cheeky takeover bid, one suspects, will have come as a blow to the corporate ego. It had to be rejected, of course, because it would have been an act of desperation to contemplate an all-share deal on “low premium” terms at today’s valuation. Life is tough for easyJet, a UK-skewed operator more exposed than most to UK travel restrictions and the absurd price of PRC tests, but this is not a moment to give up.

But, if not Wizz, where’s the fizz supposed to come from? Chief executive Johan Lundgren’s answer was a thumping £1.2bn rights issue and, in effect, a call for shareholders to be patient, which won’t set many pulses racing.

In its own terms, the fundraising makes sense. The fresh funds will repair a balance sheet where net debt has risen from £326m to £2bn during the pandemic. The company can now cope with a cold travel winter and a slow 2022. And there’ll be a few quid to try to grab prime landing slots at airports such as Gatwick, Paris Orly and Amsterdam Schiphol.

In theory, there’s no reason why easyJet can’t ultimately reclaim its former position and, possibly, emerge bigger from the crisis. But the first task for Stephen Hester, who arrives as chairman at the end of the year, is clear: ensure that the shareholders genuinely support a reinvigoration plan that may take a while. If the European short-haul market is consolidating, the next takeover approach may be serious.

Governance abomination – but we should probably relax

Oxford Nanopore, the DNA sequencing and analytics spin-out from Oxford University, is the current “hot” company in UK biotech circles. The pandemic, runs the thinking, hasn’t just delivered a big advance in revenues from Covid-related contracts, but has also transformed horizons in the business of “analysis of any living thing”.

So there will be relief among sensitive UK politicians that Nanopore is sticking to plans to go public in London rather than New York. “It’s an urban myth that you can do much better on Nasdaq,” says chief executive Gordon Sanghera. That’s the sprit.

But there is a US-style feature to the float that, potentially, could cause traditional UK shareholders to splutter. It’s the “limited anti-takeover” share, to be held by Sanghera, that carries the right to refuse an unwanted takeover bid for a period of three years.

A governance abomination? Strictly speaking, yes: equal rights for equal economic risk remains an excellent principle. But, equally, a one-size-fits-all approach feels too rigid. The case for exceptionalism for Nanopore is that one genuinely wants to see the company have a shot at converting its intellectual patents into commercial success.

By way of example of what’s possible in this field, look at US gene-sequencing company Illumina, which back in 2012 fended off a $6.8bn (£4.9bn) bid from the giant Roche. Nine years later, Illumina’s value has risen tenfold. There is no guarantee, of course, that Nanopore, valued at £2.4bn in its last private funding round, will be able to achieve anything comparable. But, in the interest of the broader UK biotech industry, one would like to see it have a go.

The three-year “sunset” clause applies to the anti-takeover shares, which is a critical feature: the control-freakery won’t last for ever. The structure means Nanopore can’t currently have a so-called “premium” market listing, but is within the spirit of Lord Hill’s recent review of the listing regime. We should probably relax.

Salad days for Caesars, but spilt milk for ex-William Hill shareholders

The winner in the latest shakeup in the deal-a-minute gambling industry is Caesars. The Las Vegas casino company was clear when it bought William Hill last year for £2.7bn that its interest was only the two companies’ joint venture in the US. Now it has managed to offload the unwanted bit – William Hill International, the non-US assets, including 1,400 shops in the UK – for £2.2bn to 888 Holdings.

In other words, it’s recouped most of its outlay, and has control of the asset it wanted in the boom-boom liberalising US sports betting market. William Hill’s former shareholders approved last year’s sale to Caesars, but may now regret it. Their company was one of the first in the UK to spot the potential in the US. Instead, the likes of Flutter are still at the table and winning big.

Contributor

Nils Pratley

The GuardianTramp

Related Content

Article image
EasyJet shares come down to earth after years of stratospheric returns
The budget airline has hit strong headwinds, which will take a few years to disperse, but it’s well placed to take advantage of weakness in the sector

Nils Pratley

06, Oct, 2016 @6:56 PM

Article image
Apollo lands with the frontrunner in Morrisons takeover mission
By dropping solo bid plan and teaming up with Fortress, private equity firm is just one of the crew

Nils Pratley

20, Jul, 2021 @7:06 PM

Article image
EasyJet should navigate financial pressures, but clouds haven't cleared yet
Even if there’s delayed take-off for Covid vaccines, the budget airline has options

Nils Pratley

17, Nov, 2020 @7:59 PM

Article image
No need for Entain to rush into accepting MGM Resorts offer | Nils Pratley
Owner of Ladbrokes and Coral right to take a wait-and-see approach ahead of US online betting bonanza

Nils Pratley

04, Jan, 2021 @7:37 PM

Article image
Hedge funds have a lot to answer for, no wonder they're paid so well
Triumph of sector has been to enter the investment mainstream while clinging to fees that belong to age of bespoke tailoring

Nils Pratley

10, May, 2016 @6:44 PM

Article image
Oxford Nanopore float offers London a proper tech future
Planned IPO of life science group will test LSE’s appetite for funding high-growth tech

Nils Pratley

30, Mar, 2021 @6:30 PM

Article image
A prized UK biotech firm looks to Wall Street, much to Rishi Sunak’s dismay
Vaccitech, the Oxford-based firm behind the AstraZeneca vaccine, is a high-profile float that slipped away

Nils Pratley

07, Apr, 2021 @7:03 PM

Article image
Post-Brexit London is open for business (no matter how grubby)
The City watchdog’s rewriting of the premium listing rules to accommodate a potential mega-listing in London of Aramco is deplorable

Nils Pratley

13, Jul, 2017 @10:57 PM

Article image
The Didi clampdown marks a sea change in the politics of global investment
For Beijing ‘data security’ now trumps the old desire to have its tech firms seen as global champions

Nils Pratley

06, Jul, 2021 @6:54 PM

Article image
Sky News is worth saving – it's why it's central to a deal
Murdoch will see regulator’s qualified ‘no’ as a fudge. If he sells Sky News, a deal is back on

Nils Pratley

23, Jan, 2018 @6:29 PM